Laura Allington

University College London Hospitals NHS Foundation Trust

Laura qualified as a Therapeutic Radiographer in 1995 and commenced her career at The Royal Marsden Hospital. Since moving to UCLH in 1999, she has held a number of positions across both the pre-treatment and treatment areas of radiotherapy. For the past 16 years she has played a key role in implementing new treatment techniques and influencing changes in practice within the department. Some of this work formed part of a Masters level degree that she completed in 2016. Since 2015, Laura has been involved in all aspects of developing the NHS UK proton service which has included equipment procurement, patient pathway design, workforce modelling and patient engagement. For the past 2 years, she has held the position of Operational Lead for Proton Beam Therapy at UCLH.

dont miss

Operational challenges of planning a new NHS high energy proton service

Perspective overview from University College London Hospitals NHS Foundation Trust of implementing the NHS high energy proton therapy service with the Christie NHS Foundation Trust.

Laura Allington will be speaking in the following theatre:

EVEN MORE SEMINARS

  • Dr Richter-Heine: Speaking at the Oncology Convention

    Dr Richter-Heine
    Praxisgemeinschaft im Camparihaus

    Benefits of supporting medical garments in breast surgery

  • Christopher Curtis: Speaking at the Oncology Convention

    Christopher Curtis
    The Swallows Head & Neck Cancer Charity

    From Cancer to the Palace in 6 years

  • Jocelyn Harding CEB DipDH: Speaking at the Oncology Convention

    Jocelyn Harding CEB DipDH
    Oralieve UK

    The importance of mouth care for cancer patients

  • Professor Sun Myint: Speaking at the Oncology Convention

    Professor Sun Myint
    Clatterbridge Cancer Centre (Private Clinic)

    Rectal cancer- Do patients have a choice?

  • Prof. András SZÁSZ: Speaking at the Oncology Convention

    Prof. András SZÁSZ
    St. Istvan University

    Modulated electrohyperthermia (mEHT) for advanced malignant tumors